Prosecution Insights
Last updated: August 18, 2026
Application No. 17/926,559

AZABICYCLIC(THIO)AMIDES AS FUNGICIDAL COMPOUNDS

Non-Final OA §112
Filed
Nov 18, 2022
Priority
May 19, 2020 — EU 20175375.3 +1 more
Examiner
PAK, JOHN D
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Bayer Aktiengesellschaft
OA Round
3 (Non-Final)
52%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allowance Rate
524 granted / 1004 resolved
-7.8% vs TC avg
Strong +38% interview lift
Without
With
+37.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
38 currently pending
Career history
1041
Total Applications
across all art units

Statute-Specific Performance

§101
3.2%
-36.8% vs TC avg
§103
42.1%
+2.1% vs TC avg
§102
13.4%
-26.6% vs TC avg
§112
29.2%
-10.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1004 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6/12/2026 has been entered. Claims 1, 3-9, 11-12, and 16 are pending in this application. Withdrawn ground of rejection The outstanding nonstatutory double patenting ground of rejection as being unpatentable over claims of copending Application No. 18/009,681 (reference application) in view of Wada et al. (US 5,154,750) and Takabe et al. (US 5,403,816) is withdrawn in view of the amendment to the claims filed on 6/12/2026. Amendment to claim 1, which limits R3 to H, F, Cl, or C1-4 alkyl overcomes this ground of rejection, because the corresponding substituent in said reference application requires a ring-containing moiety. 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 3-9, 11-12, and 16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. (1) In claim 1, Y is defined to form “(II-a) to (II-aa).” However, structures for (II-q), (II-r), (II-s), and (II-t) are missing. Claims 6 and 11 have the same indefiniteness issue of reciting Y as “(II-a) to (II-aa)” but (II-q), (II-r), (II-s), and (II-t) are missing. (2a) In claim 1, the definition “p is 0, 1, 2, 3 or 4, and has the same meaning in Formula I and Formulae IIa-IIaa” (emphases added) lacks antecedent basis. Formulae IIa to IIaa were not established in claim 1 prior to this definition of p. Also, even if there were proper antecedent basis, claim 1 is missing formulae (II-q), (II-r), (II-s), and (II-t). (2b) In claim 3, “p is 0, 1 or 2 and has the same meaning in Formula I and Formulae IIa-IIv” (emphases added) is indefinite for several reasons. First, claim 3 has limited Y to a smaller group of formulas, so not all of formulae IIa to IIv are readable on claim 3. For example, formula IIc is not readable on claim 3. Second, the formulas that are covered by Y in claim 3 are extremely confusing. As shown below, Y includes II-i, but there is no structural formula for II-i in claim 3: [AltContent: rect] Instead of the structure for II-i, structure for II-j is set forth; but as can be seen from above, II-j was not recited for ring Y in this claim. Third, p is defined as having the same meaning as Formula IIa to IIv in claim 3, but strangely and most confusingly formulas other than Formula IIa to IIv are set forth in claim 3, e.g., Formula II-g, II-h, etc. (2c) In claim 11, “P is 0, 1, 2, 3, or 4, and has the same meaning in Formula I-a and Formulae IIa-IIaa” is indefinite. Similar to (2b), supra, formulae II-q, II-r, II-s, and II-t are missing from “Formulae IIa-IIaa.” (2d) Claim 11 has the same indefiniteness issue in the phrase, “p is 0 … or 4, and has the same meaning in Formula I-a and Formulae IIa-IIaa.” Formulae II-q, II-r, II-s, and II-t are missing from “Formulae IIa-IIaa.” (3) In claim 6, there should be a comma after “C1-C4-alkyl” as shown below (see page 22 of the 6/12/2026 claim set): PNG media_image2.png 50 412 media_image2.png Greyscale (4) In claim 12, “p is 0, 1, 2, 3 or 4, and has the same meaning in Formula I-a-1 and Formulae IIa-IIaa” is indefinite. Formulae II-q, II-r, II-s, and II-t are missing from “Formulae IIa-IIaa.” (5) In claim 12, the last two lines, “in the presence of a base and optionally in the presence of a transition metal catalyst, if appropriate additionally in the presence of a ligand” are indefinite. It is unclear when it would be appropriate or not appropriate. (6) Dependent claims are included in this ground of rejection because they do not cure the deficiencies of their base claims. Response to Applicant’s arguments filed on 6/12/2026 Applicant’s arguments that the previous issues of indefiniteness have been addressed are noted, but the claim set presented herein introduce additional indefiniteness issues, as fully detailed above. 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 3 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. In dependent claim 3, II-r and II-s are recited for the ring Y, but these rings were not part of the definition of Y in the independent claim 1. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. For these reasons, all claims must be rejected again. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to JOHN PAK whose telephone number is (571)272-0620. The Examiner can normally be reached on Monday to Friday from 8:30 AM to 5 PM. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's SPE, Fereydoun Sajjadi, can be reached on (571)272-3311. The fax phone number for the organization where this application or proceeding is assigned is (571)273-8300. Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center for authorized users only. Should you have questions about access to Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/patents/uspto-automated- interview-request-air-form. /JOHN PAK/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Show 1 earlier event
Jul 15, 2025
Non-Final Rejection mailed — §112
Oct 15, 2025
Response Filed
Dec 12, 2025
Final Rejection mailed — §112
Feb 12, 2026
Response after Non-Final Action
Feb 24, 2026
Examiner Interview (Telephonic)
Jun 12, 2026
Request for Continued Examination
Jun 16, 2026
Response after Non-Final Action
Jun 30, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12692238
SUBSTITUTED PYRIDAZINONE HERBICIDES
3y 1m to grant Granted Jul 28, 2026
Patent 12685310
Kit for the treatment of seeds
3y 5m to grant Granted Jul 21, 2026
Patent 12677831
Herbicidal Composition Comprising Of Phenylpyrazoline And Triazinone Compounds
2y 10m to grant Granted Jul 14, 2026
Patent 12678396
Natural Oil Composition for Improving Hair Growth
2y 1m to grant Granted Jul 14, 2026
Patent 12673942
AZABICYCLYL-SUBSTITUTED HETEROCYCLES AS FUNGICIDES
3y 7m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
52%
Grant Probability
90%
With Interview (+37.6%)
3y 1m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1004 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month